Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676672 | 1.00 | TLR2 (0.45) | TLR2CASP3MDM4TP53PTPN1 | |
| SCHEMBL26262664 | 1.00 | TLR2 (0.45) | TLR2CASP3MDM4TP53PTPN1 | |
| SCHEMBL30919311 | 0.96 | PTPN1 (0.46) | TLR2PTPN1 | |
| SCHEMBL29938622 | 0.93 | PTPN1 (0.49) | TLR2CASP3PTPN1 | |
| SCHEMBL18452568 | 0.93 | PTPN1 (0.49) | TLR2CASP3PTPN1 | |
| SCHEMBL30919318 | 0.93 | PTPN1 (0.46) | TLR2PTPN1 | |
| SCHEMBL30948796 | 0.91 | CASP3 (0.46) | TLR2CASP3MDM4TP53KMT2A | |
| SCHEMBL26940363 | 0.91 | CASP3 (0.46) | TLR2CASP3MDM4TP53KMT2A | |
| SCHEMBL3044166 | 0.89 | TLR2 (0.46) | TLR2CASP3MDM4TP53KMT2A | |
| SCHEMBL30948677 | 0.89 | TLR2 (0.46) | TLR2CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-113677338-A | Method for preparing DON prodrug from L-pyroglutamic acid | 羿尊生物医药股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
| EP-3328827-A1 | PRODRUGS OF GLUTAMINE ANALOGS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | TLR2 4356/4885CASP3 2577/4885MDM4 1014/4885 |
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | TLR2 3537/4885CASP3 4114/4885MDM4 755/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | TLR2 4364/4885CASP3 2232/4885MDM4 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.